Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Gemini Therapeutics logo — Pioneering precision treatments for genetic eye diseases wit...

Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships.

Founded 2015 Post-IPO Equity Total: $139.50M Biopharma, Biotechnology +1

General Information

Company Name Gemini Therapeutics
Founded Year 2015
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Gemini Therapeutics. To contact Gemini Therapeutics, visit geminitherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Gemini Therapeutics compare?

A PDF of Gemini Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Gemini Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Gemini Therapeutics

Gemini Therapeutics, established in 2015, is a precision medicine company that focuses on developing innovative therapeutics for genetically defined dry age-related macular degeneration (AMD) and related rare genetic conditions. Their diverse pipeline includes monoclonal antibodies, recombinant proteins, and gene therapies which target molecular abnormalities in patients with significant clinical needs. The company has secured a $95.00M Post-IPO Equity investment on 08 February 2021 from a notable list of investors including Atlas Venture, Lightstone Ventures, Boxer Capital, Wellington Management, Acorn Bioventures, Fidelity, Foresite Capital, Suvretta Capital Management, DAFNA Capital Management, LLC, and Alyeska Investment Group. The company's slogan, "Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships," reflects its commitment to leveraging global academic collaborations to advance potentially groundbreaking therapeutic solutions. With its focus on Biopharma, Biotechnology, and Health Care industries, Gemini Therapeutics is positioned to make significant contributions to the precision medicine landscape.

Business keywords: Precision Medicine, Genetic Eye Diseases, Therapeutics, Molecular Abnormalities, Monoclonal Antibodies, Recombinant Proteins, Gene Therapies, Rare Genetic Conditions, Dry Age-Related Macular Degeneration, Pipeline Development, Academic Collaborations, Life Science Investors, Innovation, First-in-Class Therapeutics, Global Partnerships

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $95.00M 10
Atlas Venture Lightstone Ventures Boxer Capital
Atlas Venture, Lightstone Ventures +8
08 Feb 2021
Series A $42.50M -
17 Oct 2017
Seed Round $2.00M -
19 Apr 2016

Gemini Therapeutics Alternatives & Competitors

Gemini Therapeutics vs
Elixirgen Therapeutics, Inc.
Elixirgen Therapeutics, Inc. United States

Reimagine the Power of RNA

Venture round
13 employees
Biotechnology, Health Care
Gemini Therapeutics vs
Salutaris Medical Devices
Salutaris Medical Devices United States

Pioneering breakthroughs in treating eye diseases with precision radiotherapy.

Venture round
3 employees
Biotechnology, Health Care

FAQ About Gemini Therapeutics

Pioneering precision treatments for genetic eye diseases with a robust pipeline of innovative therapeutics backed by global academic partnerships.
Gemini Therapeutics was founded in 2015.
Gemini Therapeutics operates in Biopharma, Biotechnology and Health Care. Its work centres on Precision Medicine, Genetic Eye Diseases, Therapeutics and Molecular Abnormalities.
Gemini Therapeutics has completed 3 funding rounds, raising a total of $139.50M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Gemini Therapeutics include Elixirgen Therapeutics, Inc., Salutaris Medical Devices. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Gemini Therapeutics and Elixirgen Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Gemini Therapeutics, https://bouncewatch.com/company/gemini-therapeutics, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout